Page last updated: 2024-11-11

iditol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

iditol: RN refers to L-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

L-iditol : The L-enantiomer of iditol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5460044
CHEBI ID18202
SCHEMBL ID435775
MeSH IDM0220760

Synonyms (27)

Synonym
1q2h9gc12e ,
unii-1q2h9gc12e
l-idit
(2s,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol
CHEBI:18202
karion
hexahydroxyhexane
hexahydric alcohol
l-iditol
C01507
488-45-9
I0725
iditol
SCHEMBL435775
FBPFZTCFMRRESA-UNTFVMJOSA-N
AKOS024258141
W-202860
mfcd00064289
l-iditol, >=98%
iditol, l-
Q27102896
(2s,3r,4r,5s)-hexane-1,2,3,4,5,6-hexaol
D91196
AS-56025
DTXSID901337629
CS-0082969
HY-121654
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
fungal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
iditol
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (46.15)18.7374
1990's1 (7.69)18.2507
2000's5 (38.46)29.6817
2010's1 (7.69)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.13 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index40.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]